Regeneron Pharmaceuticals, Inc. Announces Quarterly Dividend of $0.94 (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a quarterly dividend on Wednesday, April 29th. Investors of record on Wednesday, May 20th will be paid a dividend of 0.94 per share by the biopharmaceutical company on Thursday, June 4th. This represents a c) dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th.

Regeneron Pharmaceuticals has a payout ratio of 9.6% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Regeneron Pharmaceuticals to earn $42.14 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 8.9%.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $694.18 on Thursday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $821.11. The firm has a 50 day moving average of $758.31 and a two-hundred day moving average of $735.37. The firm has a market capitalization of $73.39 billion, a PE ratio of 16.79, a P/E/G ratio of 1.71 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.10 by $0.37. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.45 billion. During the same period in the previous year, the firm posted $8.22 earnings per share. The firm’s quarterly revenue was up 19.0% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals will post 35.98 EPS for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 3,774 shares of company stock worth $2,942,738. Insiders own 7.02% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Seelaus Asset Management LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter worth about $275,000. Childress Capital Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 38.6% in the 1st quarter. Childress Capital Advisors LLC now owns 567 shares of the biopharmaceutical company’s stock valued at $438,000 after buying an additional 158 shares during the period. Flatrock Wealth Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $291,000. Jackson Thornton Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 10.2% during the 1st quarter. Jackson Thornton Wealth Management LLC now owns 1,091 shares of the biopharmaceutical company’s stock worth $817,000 after buying an additional 101 shares during the last quarter. Finally, Resonant Capital Advisors LLC raised its position in shares of Regeneron Pharmaceuticals by 16.0% during the 1st quarter. Resonant Capital Advisors LLC now owns 501 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 69 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.